Edition:
United Kingdom

Biotechnology & Medical Research

Page 1

Mabvax Therapeutics Holdings Provides Business Strategy Update

Tuesday, 16 Jan 2018

Jan 16 (Reuters) - Mabvax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS HOLDINGS, INC. PROVIDES BUSINESS STRATEGY UPDATE.MABVAX THERAPEUTICS - ON TRACK TO EXECUTE CORPORATE AND CLINICAL MILESTONES IN FIRST HALF OF 2018.MABVAX - CURRENTLY IN "ADVANCED DISCUSSIONS" WITH A VARIETY OF INTERESTED PARTIES FOR POTENTIAL MULTIPLE DEAL PROPOSALS.

Veracyte Announces Strategic Realignment And New Appointments To Advance Commercial Growth

Monday, 8 Jan 2018

Jan 8 (Reuters) - Veracyte Inc ::VERACYTE ANNOUNCES STRATEGIC REALIGNMENT AND NEW APPOINTMENTS TO ADVANCE COMMERCIAL GROWTH.- COMPANY REITERATES 2017 REVENUE AND CASH BURN GUIDANCE.- IS CONSOLIDATING CLINICAL, MEDICAL AND RESEARCH AND DEVELOPMENT FUNCTIONS INTO ONE DEPARTMENT.FY2017 EARNINGS PER SHARE VIEW $-0.87, REVENUE VIEW $71.3 MILLION -- THOMSON REUTERS I/B/E/S.

Ohr Pharmaceutical Announces Efficacy Results From The Mako Study In Wet-Amd

Friday, 5 Jan 2018

Jan 5 (Reuters) - Ohr Pharmaceutical Inc ::OHR PHARMACEUTICAL ANNOUNCES EFFICACY RESULTS FROM THE MAKO STUDY IN WET-AMD.OHR PHARMACEUTICAL INC - ‍TOPLINE DATA FROM MAKO STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT​.OHR PHARMACEUTICAL INC - "WE ARE VERY DISAPPOINTED WITH OUTCOME OF MAKO STUDY".OHR PHARMACEUTICAL INC - ‍INTEND TO EVALUATE STRATEGIC ALTERNATIVES TO "MAXIMIZE SHAREHOLDER VALUE"​.OHR PHARMA - SUBJECTS RECEIVING SQUALAMINE COMBINATION THERAPY ACHIEVED MEAN GAIN OF 8.33 LETTERS FROM BASELINE VERSUS 10.58 FROM LUCENTIS MONOTHERAPY.

MBK decides to sell shares of Ad Me Tech

Monday, 18 Dec 2017

Dec 18 (Reuters) - MBK Co Ltd <3121.T> ::Says it decided to sell 175,000 shares in Ad Me Tech Co Ltd <<<7778.T>>>, cutting stake to 2.87 percent (115,000 shares) from 9.74 percent (390,000 shares) currently, on Dec. 19.Says the gain on sales of investment securities will be 27 million yen .

AmpliPhi Biosciences Says Engaged Ladenburg Thalmann & Co To Review Strategic Alternatives

Thursday, 14 Dec 2017

Dec 14 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES PROVIDES CORPORATE AND STRATEGIC UPDATE.AMPLIPHI BIOSCIENCES - ENGAGED LADENBURG THALMANN & CO. INC. TO REVIEW STRATEGIC ALTERNATIVES.

Zhongyuan Union Cell & Gene Engineering unit liquidates Tianjin-based hospital management firm

Thursday, 30 Nov 2017

Nov 30 (Reuters) - Zhongyuan Union Cell & Gene Engineering Co Ltd <600645.SS>:Says its unit liquidated Tianjin-based hospital management firm .

Formycon confirms management board members until mid-2022

Thursday, 16 Nov 2017

Nov 16 (Reuters) - FORMYCON AG ::DGAP-NEWS: FORMYCON AG: FORMYCON SETS COURSE FOR THE FUTURE AND CONFIRMS MANAGEMENT BOARD MEMBERS UNTIL MID-2022.‍CONTRACTS OF CEO CARSTEN BROCKMEYER AND CFO NICOLAS COMBÉ EXTENDED UNTIL JUNE 30, 2022​.‍APPOINTMENT OF COO STEFAN GLOMBITZA REMAINS UNCHANGED​.

Ampliphi biosciences reports ‍cash and cash equivalents as of Sept 30 totaled $7.7 mln

Tuesday, 14 Nov 2017

Nov 14 (Reuters) - Ampliphi Biosciences Corp :Ampliphi Biosciences reports third quarter 2017 financial results and business highlights.Ampliphi Biosciences Corp - ‍Cash and cash equivalents as of September 30, 2017 totaled $7.7 million.Ampliphi Biosciences Corp - ‍Anticipates current financial resources will provide sufficient cash to fund operations until mid-2018​.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary